SCHEMBL3952147

SCHEMBL3952147

CC(=O)NCC1CCCNC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBK Q96KB5 5/20 0.45
CPN1 P15169 1/20 0.44
CPB2 Q96IY4 1/20 0.44
EPHX1 P07099 1/20 0.43
ALOX15 P16050 1/20 0.41
KMT2A Q03164 2/20 0.41
CHEK1 O14757 2/20 0.40
SLC6A1 P30531 2/20 0.40
SLC6A11 P48066 1/20 0.40
TSHR P16473 1/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
FUCA1 P04066 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SLC6A13 Q9NSD5 1/20 0.40
FPR3 P25089 1/20 0.39
FPR2 P25090 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM3 P20309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13186049 1.00 PBK (0.45) PBKCPN1CPB2EPHX1ALOX15
SCHEMBL13212506 1.00 PBK (0.45) PBKCPN1CPB2EPHX1ALOX15
SCHEMBL617644 0.89 ALOX15 (0.51) EPHX1ALOX15SLC6A1SLC6A11TSHR
SCHEMBL9044696 0.89 ALOX15 (0.51) EPHX1ALOX15SLC6A1SLC6A11TSHR
SCHEMBL617850 0.89 ALOX15 (0.51) EPHX1ALOX15SLC6A1SLC6A11TSHR
Hydrochloric Acid SCHEMBL715762 0.87 ALOX15 (0.50) EPHX1ALOX15SLC6A1SLC6A11TSHR
Hydrochloric Acid SCHEMBL715763 0.87 ALOX15 (0.50) EPHX1ALOX15SLC6A1SLC6A11TSHR
SCHEMBL477374 0.84 CYP2D6 (0.51) PBKCPN1CPB2EPHX1KMT2A
SCHEMBL5649078 0.84 CYP2D6 (0.51) PBKCPN1CPB2EPHX1KMT2A
SCHEMBL2768724 0.84 CYP2D6 (0.51) PBKCPN1CPB2EPHX1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493444-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2016-11-15 US disclosed
US-9493444-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2016-11-15 US disclosed
EP-2807154-B1 AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2015-12-23 EP disclosed
US-20150005294-A1 AZAHETEROCYCLIC COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-01-01 US disclosed
US-20150005294-A1 AZAHETEROCYCLIC COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-01-01 US disclosed
WO-2013110433-A1 AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2013-08-01 WO disclosed
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed
WO-2010149684-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-29 WO disclosed
CN-101460507-A Thiazolyldihydroindazoles BOEHRINGER INGELHEIM INT (DE) 2009-06-17 CN disclosed
EP-2018386-A1 THIAZOLYLDIHYDROINDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-01-28 EP disclosed
US-20070259855-A1 THIAZOLYL-DIHYDRO-INDAZOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-08 US disclosed
WO-2007115930-A1 THIAZOLYLDIHYDROINDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed
CN-1665506-A 2, 5-substituted pyrimidine derivatives as CCR-3 receptor antagonists IX HOFFMANN LA ROCHE (CH) 2005-09-07 CN disclosed
US-5147882-A Cardiovascular disorders KARL THOMAE GMBH (DE) 1992-09-15 US disclosed
EP-0450429-A1 Cyclophanes, process for their preparation and pharmaceuticals containing them Dr. Karl Thomae GmbH (DE) 1991-10-09 EP disclosed
US-5051509-A Antibiotics CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1991-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259855-A1 THIAZOLYL-DIHYDRO-INDAZOLE ROR1, RORB, RORA PBK 2545/4885CPN1 4790/4885CPB2 4432/4885
US-20150005294-A1 AZAHETEROCYCLIC COMPOUNDS PCNA, CDKN1A, CCNC PBK 984/4885CPN1 4692/4885CPB2 4161/4885
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO MC2R, REN, CYP11B2 PBK 3682/4885CPN1 1793/4885CPB2 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.